| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abstract
|
|
|
1997
|
33 |
12 |
p. 2136-
1 p.
|
artikel
|
| 2 |
Abstract
|
|
|
1997
|
33 |
12 |
p. 2136-
1 p.
|
artikel
|
| 3 |
Abstract
|
|
|
1997
|
33 |
12 |
p. 2138-
1 p.
|
artikel
|
| 4 |
Abstract
|
|
|
1997
|
33 |
12 |
p. 2139-
1 p.
|
artikel
|
| 5 |
Abstract
|
|
|
1997
|
33 |
12 |
p. 2139-
1 p.
|
artikel
|
| 6 |
Abstract
|
|
|
1997
|
33 |
12 |
p. 2137-
1 p.
|
artikel
|
| 7 |
Abstract
|
|
|
1997
|
33 |
12 |
p. 2137-
1 p.
|
artikel
|
| 8 |
Abstract
|
|
|
1997
|
33 |
12 |
p. 2138-
1 p.
|
artikel
|
| 9 |
Activation of trk-A but not trk-B signal transduction pathway inhibits growth of Neuroblastoma cells
|
Lucarelli, E
|
|
1997
|
33 |
12 |
p. 2068-2070
3 p.
|
artikel
|
| 10 |
Activity of a 40kDa RNA-binding protein correlates with MYCN and c-fos mRNA stability in human neuroblastoma
|
Chagnovich, D.
|
|
1997
|
33 |
12 |
p. 2064-2067
4 p.
|
artikel
|
| 11 |
alterations of the tumour suppressor gene DCC in Neuroblastoma
|
Kong, X.-T
|
|
1997
|
33 |
12 |
p. 1962-1965
4 p.
|
artikel
|
| 12 |
Analysis of candidate gene co-amplification with MYCN in neuroblastoma
|
George, R.E
|
|
1997
|
33 |
12 |
p. 2037-2042
6 p.
|
artikel
|
| 13 |
Analysis of 1;17 translocation breakpoints in neuroblastoma: implications for mapping of neuroblastoma genes
|
Van Roy, N
|
|
1997
|
33 |
12 |
p. 1974-1978
5 p.
|
artikel
|
| 14 |
Angiostatic treatment of neuroblastoma
|
Wassberg, E
|
|
1997
|
33 |
12 |
p. 2020-2023
4 p.
|
artikel
|
| 15 |
A product of DAN, a novel candidate tumour suppressor gene, is secreted into culture medium and suppresses DNA synthesis
|
Nakamura, Y
|
|
1997
|
33 |
12 |
p. 1986-1990
5 p.
|
artikel
|
| 16 |
Betulinic acid induces apoptosis in human neuroblastoma cell lines
|
Schmidt, M.L
|
|
1997
|
33 |
12 |
p. 2007-2010
4 p.
|
artikel
|
| 17 |
Buthionine sulphoximine alone and in combination with melphalan (L-PAM) is highly cytotoxic for human neuroblastoma cell lines
|
Anderson, C.P
|
|
1997
|
33 |
12 |
p. 2016-2019
4 p.
|
artikel
|
| 18 |
Clinical relevance of CD44 cell surface expression and MYCN gene amplification in neuroblastoma
|
Combaret, V
|
|
1997
|
33 |
12 |
p. 2101-2105
5 p.
|
artikel
|
| 19 |
Coexpression of mRNA for the full-length neurotrophin receptor trk-C and trk-A in favourable neuroblastoma
|
Svensson, T
|
|
1997
|
33 |
12 |
p. 2058-2063
6 p.
|
artikel
|
| 20 |
Correlation of MYCN amplification, Trk-A and CD44 expression with clinical stage in 250 patients with neuroblastoma
|
Kramer, K
|
|
1997
|
33 |
12 |
p. 2098-2100
3 p.
|
artikel
|
| 21 |
Delimitation of a critical tumour suppressor region at distal 1p in neuroblastoma tumours
|
Martinsson, T
|
|
1997
|
33 |
12 |
p. 1997-2001
5 p.
|
artikel
|
| 22 |
Detection of Neuroblastoma cells in CD34+ selected peripheral stem cells using a combination of tyrosine hydroxylase nested RT–PCR and anti-Ganglioside GD2 immunocytochemistry
|
Lode, H.N
|
|
1997
|
33 |
12 |
p. 2024-2030
7 p.
|
artikel
|
| 23 |
DNA-Topoisomerase I, a new target for the treatment of neuroblastoma
|
Vassal, G
|
|
1997
|
33 |
12 |
p. 2011-2015
5 p.
|
artikel
|
| 24 |
Drug resistance in human neuroblastoma cell lines correlates with clinical therapy
|
Keshelava, N
|
|
1997
|
33 |
12 |
p. 2002-2006
5 p.
|
artikel
|
| 25 |
Editorial
|
|
|
1997
|
33 |
12 |
p. 1909-1910
2 p.
|
artikel
|
| 26 |
Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the pediatric oncology group
|
Strother, D
|
|
1997
|
33 |
12 |
p. 2121-2125
5 p.
|
artikel
|
| 27 |
Evidence that the MYCN oncogene regulates MRP gene expression in neuroblastoma
|
Norris, M.D
|
|
1997
|
33 |
12 |
p. 1911-1916
6 p.
|
artikel
|
| 28 |
Expression and function of Trk-C in favourable human neuroblastomas
|
Yamashiro, D.J
|
|
1997
|
33 |
12 |
p. 2054-2057
4 p.
|
artikel
|
| 29 |
Expression of a 260kDa Neuroblastoma Surface Antigen, the Target of Cytotoxic Natural Human IgM: Correlation to MYCN Amplification and Effects of Retinoic Acid
|
David, K
|
|
1997
|
33 |
12 |
p. 1937-1941
5 p.
|
artikel
|
| 30 |
HuD, a neuronal-specific RNA-binding protein, is a potential regulator of MYCN expression in human neuroblastoma cells
|
Ross, R.A
|
|
1997
|
33 |
12 |
p. 2071-2074
4 p.
|
artikel
|
| 31 |
Human krüppel-related 3 (HKR3): a candidate for the 1p36 neuroblastoma tumour suppressor gene?
|
Maris, J.M
|
|
1997
|
33 |
12 |
p. 1991-1996
6 p.
|
artikel
|
| 32 |
Interleukin-1β converting enzyme (ICE) is preferentially expressed in neuroblastomas with favourable prognosis
|
Ikeda, H
|
|
1997
|
33 |
12 |
p. 2081-2083
3 p.
|
artikel
|
| 33 |
Loss of chromosome 1p may have a prognostic value in localised Neuroblastoma: results of the French NBL 90 study
|
Rubie, H
|
|
1997
|
33 |
12 |
p. 1917-1922
6 p.
|
artikel
|
| 34 |
Loss of heterozygosity for chromosome 1p in familial neuroblastoma
|
Tonini, G.P
|
|
1997
|
33 |
12 |
p. 1953-1956
4 p.
|
artikel
|
| 35 |
Loss of heterozygosity in Neuroblastomas—an Overview
|
Takita, J
|
|
1997
|
33 |
12 |
p. 1971-1973
3 p.
|
artikel
|
| 36 |
Mechanisms of in vivo antineuroblastoma activity of human natural IgM
|
Ollert, M.W
|
|
1997
|
33 |
12 |
p. 1942-1948
7 p.
|
artikel
|
| 37 |
Molecular analysis of the region of distal 1p commonly deleted in Neuroblastoma
|
White, P.S
|
|
1997
|
33 |
12 |
p. 1957-1961
5 p.
|
artikel
|
| 38 |
Molecular genetic analysis of familial neuroblastoma
|
Maris, J.M
|
|
1997
|
33 |
12 |
p. 1923-1928
6 p.
|
artikel
|
| 39 |
Monoclonal antibody to human trk-A: diagnostic and therapeutic potential in neuroblastoma
|
Kramer, K
|
|
1997
|
33 |
12 |
p. 2090-2091
2 p.
|
artikel
|
| 40 |
1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions
|
Philip, T
|
|
1997
|
33 |
12 |
p. 2130-2135
6 p.
|
artikel
|
| 41 |
Neuroblastoma cells can actively eliminate supernumerary MYCN gene copies by micronucleus formation—sign of tumour cell revertance?
|
Ambros, I.M
|
|
1997
|
33 |
12 |
p. 2043-2049
7 p.
|
artikel
|
| 42 |
Prognostic relevance of genetic alterations in the p32 region of chromosome 1 in neuroblastoma
|
Avigad, S
|
|
1997
|
33 |
12 |
p. 1983-1985
3 p.
|
artikel
|
| 43 |
Representational difference analysis and loss of heterozygosity studies detect 3p deletions in neuroblastoma
|
Hallstensson, K
|
|
1997
|
33 |
12 |
p. 1966-1970
5 p.
|
artikel
|
| 44 |
Restriction fragment length polymorphism analysis reveals different allele frequency and a linkage disequilibrium at locus D1S94 in neuroblastoma patients
|
Perri, P
|
|
1997
|
33 |
12 |
p. 1949-1952
4 p.
|
artikel
|
| 45 |
Retinoids in neuroblastoma therapy: distinct biological properties of 9-cis- and all-trans-retinoic acid
|
Lovat, P.E
|
|
1997
|
33 |
12 |
p. 2075-2080
6 p.
|
artikel
|
| 46 |
Role of neurotrophins and their receptors in human neuroblastomas: a primary culture study
|
Nakagawara, A
|
|
1997
|
33 |
12 |
p. 2050-2053
4 p.
|
artikel
|
| 47 |
Screening for neuroblastoma is ineffective in reducing the incidence of unfavourable advanced stage disease in older children
|
Woods, W.G
|
|
1997
|
33 |
12 |
p. 2106-2112
7 p.
|
artikel
|
| 48 |
Sensitive and reliable detection of genomic imbalances in human neuroblastomas using comparative genomic hybridisation analysis
|
Van Gele, M
|
|
1997
|
33 |
12 |
p. 1979-1982
4 p.
|
artikel
|
| 49 |
Somatostatin in neuroblastoma and ganglioneuroma
|
Kogner, P
|
|
1997
|
33 |
12 |
p. 2084-2089
6 p.
|
artikel
|
| 50 |
Stage IV neuroblastoma in patients over 1 year of age at diagnosis: consolidation of poor responders with combined busulfan, cyclophosphamide and melphalan followed by In vitro mafosfamide-Purged autologous bone marrow transplantation
|
Hartmann, O
|
|
1997
|
33 |
12 |
p. 2126-2129
4 p.
|
artikel
|
| 51 |
Survival from non-stage 4 neuroblastoma without cytotoxic therapy: an analysis of clinical and biological markers
|
Cheung, N.-K.V
|
|
1997
|
33 |
12 |
p. 2117-2120
4 p.
|
artikel
|
| 52 |
Telomerase activity in neuroblastoma: is it a prognostic indicator of clinical behaviour?
|
Hiyama, E
|
|
1997
|
33 |
12 |
p. 1932-1936
5 p.
|
artikel
|
| 53 |
Telomerase expression in primary neuroblastomas
|
Reynolds, C.P
|
|
1997
|
33 |
12 |
p. 1929-1931
3 p.
|
artikel
|
| 54 |
The current contribution of molecular factors to risk estimation in neuroblastoma patients
|
Berthold, F
|
|
1997
|
33 |
12 |
p. 2092-2097
6 p.
|
artikel
|
| 55 |
The international neuroblastoma risk groups (INRG): a preliminary report
|
Castleberry, R.P
|
|
1997
|
33 |
12 |
p. 2113-2116
4 p.
|
artikel
|
| 56 |
The prognostic value of MDR1 gene expression in primary untreated neuroblastoma
|
Haber, M
|
|
1997
|
33 |
12 |
p. 2031-2036
6 p.
|
artikel
|
Tijdschrift beschrijving